The goal of the High Speed Cell Sorter (HSCS) Core is to provide outstanding cell sorting and analysis service for SCC members. Flow cytometry is an essential tool for basic and translational cancer research. The analytical and preparative platforms in this Core are used to quantify, characterize, and purify cellular populations of interest for in vitro and in vivo studies by Core users. The HSCS Core was established in 2001 and has experienced rapid growth in capacity and utilization over a short period of time.
The Aims of the HSCS Core are as follows:
Aim 1. To develop and maintain flexible platforms for multiparameter cell analysis. Four 5-color and one 8-color benchtop flow cytometric analyzers are available 24/7 for use by cancer center members. Three cell sorters operated by Core staff support more sophisticated analysis involving up to 20 parameters.
Aim 2. To develop and maintain flexible platforms for multiparameter cell sorting. Three cell sorters provide a highly customizable platform that can support high speed sorting on up to 10 simultaneous parameters. Workflow is separated within the Core into three distinct domains for sorting of cells from humans, model organisms, or from potentially biohazardous samples.
Aim 3. To provide additional services that enhance the academic mission of the SCC. The HSCS Core will promote the use of flow cytometry in cancer-related research by providing technical assistance in preparation of cells for sorting or analysis, training personnel on use of flow cytometry instrumentation, and assisting with data archiving, analysis, interpretation, grant writing, and manuscript preparation.

Public Health Relevance

The High Speed Cell Sorter Core uses state-of-the-art instrumentation and highly trained personnel to assist scientists with cell measurements and manipulations that are essential for modern research in cancer biology.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Washington University
Saint Louis
United States
Zip Code
Eberth, Jan M; Josey, Michele J; Mobley, Lee R et al. (2017) Who Performs Colonoscopy? Workforce Trends Over Space and Time. J Rural Health :
Kuroki, Lindsay M; Frolova, Antonina I; Wu, Ningying et al. (2017) Yield of Cytology Surveillance After High-Grade Vulvar Intraepithelial Neoplasia or Cancer. J Low Genit Tract Dis 21:193-197
Spencer, David H; Russler-Germain, David A; Ketkar, Shamika et al. (2017) CpG Island Hypermethylation Mediated by DNMT3A Is a Consequence of AML Progression. Cell 168:801-816.e13
Cusworth, Brian M; Krasnick, Bradley A; Nywening, Timothy M et al. (2017) Whipple-specific complications result in prolonged length of stay not accounted for in ACS-NSQIP Surgical Risk Calculator. HPB (Oxford) 19:147-153
Wang, Xuya; Mooradian, Arshag D; Erdmann-Gilmore, Petra et al. (2017) Breast tumors educate the proteome of stromal tissue in an individualized but coordinated manner. Sci Signal 10:
Knoop, Kathryn A; Gustafsson, Jenny K; McDonald, Keely G et al. (2017) Microbial antigen encounter during a preweaning interval is critical for tolerance to gut bacteria. Sci Immunol 2:
Tang, Rui; Habimana-Griffin, LeMoyne M; Lane, Daniel D et al. (2017) Nanophotosensitive drugs for light-based cancer therapy: what does the future hold? Nanomedicine (Lond) 12:1101-1105
Song, Hao; Ruan, Dan; Liu, Wenyang et al. (2017) Respiratory motion prediction and prospective correction for free-breathing arterial spin-labeled perfusion MRI of the kidneys. Med Phys 44:962-973
Bandyopadhyay, Shovik; Li, Junjie; Traer, Elie et al. (2017) Cholesterol esterification inhibition and imatinib treatment synergistically inhibit growth of BCR-ABL mutation-independent resistant chronic myelogenous leukemia. PLoS One 12:e0179558
Lim, Kian-Huat; Langley, Emma; Gao, Feng et al. (2017) A clinically feasible multiplex proteomic immunoassay as a novel functional diagnostic for pancreatic ductal adenocarcinoma. Oncotarget 8:24250-24261

Showing the most recent 10 out of 1109 publications